IRWD
NASDAQ
US
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
$3.54
▼ $-0.36
(-9.23%)
Vol 1.9M
8
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$548.2M
P/E
19.2
ROE
29.3%
Margin
8.4%
D/E
56.12
Beta
0.15
52W
$1–$5
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
5
Buy
3
Hold
0
Sell
0
Strong Sell
70.0%
Buy Rating
Price Chart
Similar Stocks
PURR
Hyperliquid Strategies Inc
ALLO
Allogene Therapeutics Inc
$307.9M
PRME
Prime Medicine Inc
$626.4M
OCGN
Ocugen Inc
$421.6M
MDXG
MiMedx Group Inc
P/E 24.6
$1.0B
PROK
Prokidney Corp
$673.9M
TECX
Tectonic Therapeutic Inc
$390.4M
KYTX
Kyverna Therapeutics Inc
$537.0M
EIKN
Eikon Therapeutics Inc
CBIO
Crescent Biopharma Inc
$164.8M
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.01 | $-0.01 | $-0.02 |
| Sep 2025 | $0.10 | $0.24 | +$0.14 |
| Jun 2025 | $0.04 | $0.14 | +$0.10 |
| Mar 2025 | $-0.05 | $-0.14 | $-0.09 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $90.5M | $41.1M | $85.2M | $122.1M | $47.7M |
| Net Income | — | $2.3M | -$37.4M | $23.6M | $40.1M | -$2.3M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | 29.3% | 29.3% | 29.3% | 29.3% | 29.3% |
| P/E (TTM) | — | — | — | — | 19.94 | 19.20 |
| Net Margin | 27.7% | -2.6% | -2.6% | -2.6% | 8.4% | 8.4% |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| D/E Ratio | — | 56.12 | 56.12 | 56.12 | 56.12 | 56.12 |
| Current Ratio | 0.82 | 0.82 | 0.82 | 0.82 | 1.13 | 1.13 |
Key Ratios
ROA (TTM)
8.1%
P/S (TTM)
1.62
P/B
2.9
EPS (TTM)
$0.14
CF/Share
$-5.48
Rev Growth 3Y
-5.3%
52W High
$4.78
52W Low
$0.53
$0.53
52-Week Range
$4.78
Financial Health
Free Cash Flow
$74.6M
Net Debt
$382.3M
Cash
$215.5M
Total Debt
$597.8M
As of Dec 31, 2025
How does IRWD compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
IRWD valuation vs Biotechnology peers
P/E ratio
19.2
▲
2%
above
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.6
▼
87%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.9
▲
18%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
IRWD profitability vs Biotechnology peers
ROE
29.3%
▲
144%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
8.4%
▲
103%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
100.0%
▲
27%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
8.1%
▲
117%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
IRWD financial health vs Biotechnology peers
D/E ratio
56.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.1
▼
75%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.2
▼
84%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
IRWD fundamentals radar
IRWD
Peer median
Industry
IRWD profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
IRWD vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
DENNER ALEXANDER J
Director · Mar 17
6730800 shs
DENNER ALEXANDER J
Director · Mar 13
4451 shs
MCCOURT THOMAS A
Chief Executive Officer · Mar 10
409836 shs
MARTINI GREGORY S.
Chief Financial Officer · Mar 10
136612 shs
GASKINS TAMMI L
Officer · Mar 10
136612 shs
SHETZLINE MICHAEL
Officer · Mar 10
136612 shs
SILVER RONALD
Officer · Mar 10
163934 shs
MINARDO JOHN
Officer · Mar 10
136612 shs
MARTINI GREGORY S.
Chief Financial Officer · Feb 24
21944 shs
GASKINS TAMMI L
Officer · Feb 24
21526 shs
Last 90 days
Top Holders
Top 5: 44.29%Armistice Capital, LLC
9.83%
$50.3M
Vanguard Group Inc
9.79%
$50.1M
Sarissa Capital Management,…
9.76%
$50.0M
Blackrock Inc.
7.84%
$40.1M
Bank of America Corporation
7.07%
$36.2M
As of Dec 31, 2025
Latest News
No related news yet